Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study

Hammadi, Anwar Al; Pakran, Jaheersha; Farghaly, Mohamed; Ahmed, Haytham Mohamed; Cha, Amy; Balkan, Dilara; Afifi, Sherif; Ramachandrachar, Badarinath Chickballapur; Natarajan, Ashok; Linga, Sreenivasulu; Jefri, Khadija Al

doi:10.1007/s13555-022-00769-z

Cited by 5 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A UAE study by Al Hammadi et al extracted data from the insurance e-claims data of the Dubai Real-World Database (DRWD) and found the prevalence of mild-to-moderate AD in this population to be 5.5%. Approximately 80% of the population of Dubai, a predominately expatriate community, is covered by private insurance, and thus, the DRWD captures nearly 100% of those who are covered under private insurance [10].…”

Section: Epidemiologymentioning

confidence: 99%

“…Moderate-to-severe treated AD is associated with the highest costs, as demonstrated by a UAE study reporting the per-patient gross cost for moderate-to-severe treated AD to be USD 531.5, compared to mild-to-moderate treated AD (USD 378.38) and untreated AD (USD 144.05) [10].…”

Section: Economic Burdenmentioning

confidence: 99%

“…Atopic comorbidities such as allergic rhinitis, asthma, and food allergies are also important to consider and can drive up costs [5,10]. A child with moderate-to-severe AD can have up to a 50% risk of developing asthma and a 75% risk of developing hay fever [32].…”

Section: Economic Burdenmentioning

confidence: 99%

See 2 more Smart Citations

Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in the Arabic Population of the Middle East

Mahmoud

Yosipovitch

Attia

2023

JCM

View full text Add to dashboard Cite

Atopic dermatitis (AD) affects diverse ethnic groups with significant disparities in prevalence, disease progression, clinical outcomes, and access to care. There are limited data on AD in the Arabic population of the Middle East, yet there is a substantial economic and psychosocial burden of AD in this region with a large unmet need with regards to disease management that is critical to address. There is a trend of increasing prevalence of AD in the Arab Middle East; however, due to the large environmental, socioeconomic, and sociocultural heterogeneity of this region, prevalence varies greatly across and within countries. Similarly, clinical differences in disease presentations exist across the region, although data are limited. In this review, we will present clinical phenotypes of AD common in different regions of the Arab Middle East, and data on prevalence, genetic variations, and challenges of treatment. Further studies exploring molecular biomarkers, genetic polymorphisms, immune factors, and the microbiome of patients in the region will help to elucidate the mechanism behind ethnic differences in AD in this population as well as to understand susceptibilities and treatment response.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Economic Burdenmentioning

confidence: 99%

See 1 more Smart Citation

Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in the Arabic Population of the Middle East

Mahmoud

Yosipovitch

Attia

2023

JCM

View full text Add to dashboard Cite

show abstract

“…Patients whose AD is not controlled with topical therapies may utilize phototherapy or general systemic immunomodulators, such as methotrexate, azathioprine, and cyclosporine, or biologics such as dupilumab. Dupilumab is an interleukin 4 (IL-4) receptor antagonist that is administered subcutaneously for the treatment of moderate-to-severe AD and is approved in all of the countries surveyed in this study [ 26 , 27 ]. The oral Janus kinase (JAK) inhibitors baricitinib (approved in Egypt), abrocitinib (approved in Egypt and the UAE), and upadacitinib (approved in the UAE and Saudi Arabia) can also be used for the treatment of moderate-to-severe AD [ 1 , 25 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

“…Several emerging therapies are also available, including tralokinumab and the topical JAK inhibitor ruxolitinib [ 18 ]. Tralokinumab is approved in the UAE for the treatment of moderate-to-severe AD, while ruxolitinib is not yet approved in the Middle East [ 26 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

Patterns of Clinical Management of Atopic Dermatitis: A Survey of Three Physician Specialties in the Middle East

Ammoury

Ameen²,

Sayed

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Atopic dermatitis (AD) is a complex inflammatory disease of the skin that has a significant impact on the well-being of patients and their families. The prevalence of AD has increased in developing countries and regions, including the Middle East. Despite similarities in the presentation of the disease, there is a lack of consistent management and treatment guidelines for AD. The objective of this survey was to develop further insight into the management patterns of AD from dermatologists, pediatricians, and primary care/family medicine physicians in the Middle Eastern nations of Egypt, Lebanon, the United Arab Emirates, and Saudi Arabia. Methods: The survey was composed of 47 closedended, multiple-choice questions. These questions assessed physician and patient characteristics and treatment familiarity and approach. Results: A total of 400 physicians, including 200 dermatologists, 100 pediatricians, and 100 primary care physicians, participated in the survey. The findings provide insight into the management of AD by physician specialty within the region. A diverse array of management approaches was observed for both referral patterns and treatments for AD in the Middle East. Conclusion:The diversity of management tactics highlights the lack of a standard approach for the management of AD throughout the Middle East.

show abstract

National prevalence of atopic dermatitis in Korean adolescents from 2009 to 2022

Kattih,

Lee,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Previous studies have examined the prevalence of allergic diseases in adolescents 1–2 years after the emergence of the COVID-19 pandemic. However, more data is needed to understand the long-term impact of COVID-19 on allergic diseases. Thus, we aimed to examine the trend of the atopic dermatitis prevalence in Korean adolescents before and during the COVID-19 pandemic across 14 years. Additionally, we analyze the risk factors of atopic dermatitis (AD) based on the results. The Korean Disease Control and Prevention Agency conducted the Korea Youth Risk Behavior Web-based Survey from 2009 to 2022, from which the data for this study were obtained. Prevalence trends were compared across subgroups, and the β difference (βdiff) was calculated. We computed odds ratios to examine changes in the disease prevalence before and during the pandemic. This study included a total of 917,461 participants from 2009 to 2022. The prevalence of atopic dermatitis increased from 6.79% (95% CI 6.66–6.91) in 2009–2011 to 6.89% (95% CI 6.72–7.05) in 2018–2019, then decreased slightly to 5.82% (95% CI 5.60–6.04) in 2022. Across the 14 years, middle school student status, low parent’s highest education level, low household income, non-alcohol consumption, non-smoker smoking status, no suicidal thoughts, and no suicide attempts were associated with increased risk of atopic dermatitis, while female sex, rural residence, high BMI, low school performance, low household income, and no feelings of sadness and despair was associated with a small increase. This study examined the prevalence of atopic dermatitis across an 18-year, and found that the prevalence increased in the pre-pandemic then decreased during the start of the pandemic and remained constant throughout the pandemic. This trend could be explained mainly by the large scale social and political changes that occurred during the COVID-19 pandemic.

show abstract

Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study

Cited by 5 publications

References 56 publications

Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in the Arabic Population of the Middle East

Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in the Arabic Population of the Middle East

Patterns of Clinical Management of Atopic Dermatitis: A Survey of Three Physician Specialties in the Middle East

National prevalence of atopic dermatitis in Korean adolescents from 2009 to 2022

Contact Info

Product

Resources

About